A PROSPECTIVE AND OBSERVATIONAL STUDY OF USE AND FREQUENCY OF VARIOUS ERYTHROPOIETIN (EPO) CONGENERS AND ANALYSING THEIR EFFECTIVENESS IN THREE FORMS: DARBEPOETIN ALFA, EPOETIN ALPHA AND PEGYLATED ERYTHROPOIETIN ON DIALYSIS PATIENTS AT

Erythropoietin or EPO is a glycoprotein hormone that controls Erythropoiesis, or red blood cell production. Human EPO has a molecular weight of 34 kDa. Erythropoietin has been shown to exert its effects by binding to the erythropoietin receptor (EpoR). EPO is highly glycosylated (40 % of total molecular weight), with half-life in blood around five hours. EPO's half-life may vary between endogenous and various recombinant versions. In this study we will consider following epo on (n=105 patients) 35 patients in each arm. This study compared effectiveness between Darbepoetin alfa, Epoetin alpha and Pegylated Erythropoietin, by calculating their hemoglobin level of the patient on dialysis. A voluntary written consent will be obtained from all eligible patients who fulfill all inclusion criteria and do not meet any exclusion criteria. An average level of Hb for group of patients was recorded as: Darbepoetin alfa (before and after 7.8 and 10.9), Epoetin alfa (before and after 8.6 and 11.7) and Pegylated erythropoietin (Before and after 8.7 and 12.7). Based on the study, and observing the detailed pattern of results produced by various Erythropoietins on various patients, it can be concluded from our study Pegylated Erythropoietin showed the maximum erythropoietin effect followed by Epoetin alpha and Darbepoetin alpha